NCT06003036Completed
Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine
Accelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will undergo a session of iTBS +MRI and session of sham delivery + MRI. The order for these sessions will be blinded and randomized. The investigators predict that accelerated iTBS will enhance neurocognition relative to sham delivery.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 8 Aug 2023
- Start date
- 1 Dec 2023
- Primary completion date
- 12 Jan 2026
- Lead sponsor
- Deepak K. Sarpal, M.D.
- Diseases
- Schizophrenia
- NCT number
- NCT06003036
What you commit to
- Study type: Interventional
- Participants enrolled: 30
- From 1 Dec 2023 to the primary completion date, 12 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- history of treatment with electroconvulsive therapy
- seizure disorder or prior history of seizures on clozapine
- prior issues with intermittent theta burst stimulation/transcranial magnetic stimulation administration
- Concomitant treatment with serotonin and norepinephrine reuptake inhibitors will be examined on a case-by-case basis.
Other illness
- Serious neurologic or medical condition/treatment that impacts the brain
- Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-verified moderate or severe substance use disorder, including alcohol use disorder
Other
- a significant risk of suicidal or homicidal behavior
- cognitive or language limitations, or any other factor that would preclude subjects providing informed consent
- pregnancy or postpartum (\<6 weeks after delivery or miscarriage)
- contraindications for magnetic resonance imaging (e.g., a pacemaker)
- patients taking both bupropion and clozapine
Who the study is looking for
- A current Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-defined diagnosis of schizophrenia or schizoaffective disorder
- age 18-65 years
- at least 4 months of clozapine treatment
- history of at least 2 failed antipsychotic trials
- competency and willingness to sign informed consent
- A clinically optimized dosage of clozapine, unchanged for at least 1 month, with a minimum of 150 mg/day
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UPMC Western Psychiatric Hospital/University of Pittsburgh Coordinator of this site? Confirm its status | Pittsburgh | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.